By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lexigen Pharmaceuticals Corp. 

125 Hartwell Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-861-5300 Fax: 781-861-5301

Lexigen Pharmaceuticals Corp. is a leader in the creative development of genetically engineered proteins. The strategy of Lexigen Pharmaceuticals Corp. is to develop unique treatments for cancer and other serious, life-threatening diseases, and at the same time to develop broad technology platforms that will lead to new therapies.

Lexigen has two novel immunocytokines in clinical development. These antibody-cytokine fusion proteins target the immune system to specific cell types. Lexigen is developing the immunocytokines as cancer treatments, and simultaneously developing the immunocytokine concept as a broad, proprietary technology base.

Lexigen is an associate of Merck KGaA, Darmstadt, Germany, a multi-national pharmaceutical company with over 30,000 employees and annual revenues of approximately eight billion dollars. Thus, Lexigen combines the flexibility and creativity of a star-up biotech environment, with the financial stability, global presence, and commercial expertise of a large pharmaceutical company.

Last Updated 9-21-01

Key Statistics

Ownership: Private

Web Site: Lexigen Pharmaceuticals Corp.


Drug Discovery

Company News